|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
EP0585287B1
(en)
|
1990-07-10 |
1999-10-13 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
ATE300615T1
(de)
|
1990-08-29 |
2005-08-15 |
Genpharm Int |
Transgene mäuse fähig zur produktion heterologer antikörper
|
|
AU665025B2
(en)
|
1991-09-23 |
1995-12-14 |
Cambridge Antibody Technology Limited |
Production of chimeric antibodies - a combinatorial approach
|
|
ES2341666T3
(es)
|
1991-12-02 |
2010-06-24 |
Medimmune Limited |
Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
|
|
CA2124967C
(en)
|
1991-12-17 |
2008-04-08 |
Nils Lonberg |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
DE69333823T2
(de)
|
1992-03-24 |
2006-05-04 |
Cambridge Antibody Technology Ltd., Melbourn |
Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
|
|
NZ255101A
(en)
|
1992-07-24 |
1997-08-22 |
Cell Genesys Inc |
A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
|
|
CA2161351C
(en)
|
1993-04-26 |
2010-12-21 |
Nils Lonberg |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
GB9313509D0
(en)
|
1993-06-30 |
1993-08-11 |
Medical Res Council |
Chemisynthetic libraries
|
|
FR2707189B1
(fr)
|
1993-07-09 |
1995-10-13 |
Gradient Ass |
Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
|
|
EP0731842A1
(en)
|
1993-12-03 |
1996-09-18 |
Medical Research Council |
Recombinant binding proteins and peptides
|
|
CA2194907A1
(en)
|
1994-07-13 |
1996-02-01 |
Kouji Matsushima |
Reshaped human antibody against human interleukin-8
|
|
CA2219361C
(en)
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
|
DE60140474D1
(de)
|
2000-09-08 |
2009-12-24 |
Univ Zuerich |
Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
|
|
CA2418835A1
(en)
|
2000-10-16 |
2002-04-25 |
Phylos, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
US20030157561A1
(en)
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
|
CA2451493C
(en)
|
2001-06-22 |
2016-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
Cell growth inhibitors containing anti-glypican 3 antibody
|
|
WO2003029462A1
(en)
|
2001-09-27 |
2003-04-10 |
Pieris Proteolab Ag |
Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
|
|
AU2003234775A1
(en)
|
2002-04-30 |
2003-11-17 |
Dnavec Research Inc. |
Vector with modified protease-dependent tropism
|
|
US7750204B2
(en)
|
2002-06-05 |
2010-07-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing antibody
|
|
US8809504B2
(en)
|
2002-09-03 |
2014-08-19 |
Vit Lauermann |
Inhibitor which is deactivatable by a reagent produced by a target cell
|
|
AU2002328429A1
(en)
|
2002-09-04 |
2004-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
|
|
WO2005040229A2
(en)
|
2003-10-24 |
2005-05-06 |
Avidia, Inc. |
Ldl receptor class a and egf domain monomers and multimers
|
|
JP2005168328A
(ja)
|
2003-12-08 |
2005-06-30 |
Hokkaido Univ |
シグナル伝達活性を有する細胞質蛋白質の活性制御方法
|
|
RS53984B1
(sr)
|
2003-12-10 |
2015-10-30 |
E. R. Squibb & Sons L.L.C. |
Ip-10 antitela i njihove upotrebe
|
|
DK1735439T3
(da)
|
2004-04-12 |
2012-02-06 |
Catalyst Biosciences Inc |
Spaltning af VEGF og VEGF receptor ved hjælp af vild-type og mutant MT-SP1
|
|
CN1842540B
(zh)
|
2004-07-09 |
2012-07-04 |
中外制药株式会社 |
抗-磷脂酰肌醇蛋白聚糖3抗体
|
|
SG158150A1
(en)
|
2004-12-21 |
2010-01-29 |
Centocor Inc |
Anti-il-12 antibodies, epitopes, compositions, methods and uses
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
EP2535346B1
(en)
|
2005-08-31 |
2017-08-02 |
The Regents of The University of California |
Cellular libraries of peptide sequences (CLiPS) and methods of using the same
|
|
CA2632866A1
(en)
|
2005-12-01 |
2007-06-07 |
Domantis Limited |
Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
|
|
EA200801166A1
(ru)
|
2005-12-01 |
2008-12-30 |
Домантис Лимитед |
Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
|
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
|
|
KR101778174B1
(ko)
|
2006-07-05 |
2017-09-13 |
카탈리스트 바이오사이언시즈, 인코포레이티드 |
프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
|
|
CA2659574C
(en)
|
2006-08-02 |
2017-04-25 |
The Uab Research Foundation |
Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
|
|
EP2057191A1
(en)
|
2006-08-18 |
2009-05-13 |
Ablynx N.V. |
Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
|
|
CN101668774B
(zh)
|
2007-02-28 |
2013-06-26 |
诺维莫尼公司 |
抗干扰素诱导蛋白-10的抗体及其使用方法
|
|
CA2688433A1
(en)
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Methods for selecting protease resistant polypeptides
|
|
EP3424951A1
(en)
|
2007-06-21 |
2019-01-09 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
WO2009021754A2
(en)
|
2007-08-15 |
2009-02-19 |
Bayer Schering Pharma Aktiengesellschaft |
Monospecific and multispecific antibodies and method of use
|
|
AU2016213702C1
(en)
|
2007-08-22 |
2018-11-29 |
Cytomx Therapeutics, Inc. |
Activatable binding polypeptides and methods of identification and use thereof
|
|
CA2697032C
(en)
|
2007-08-22 |
2021-09-14 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
|
US20100189651A1
(en)
|
2009-01-12 |
2010-07-29 |
Cytomx Therapeutics, Llc |
Modified antibody compositions, methods of making and using thereof
|
|
NZ595461A
(en)
|
2009-04-10 |
2013-01-25 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
|
JP2011026294A
(ja)
|
2009-06-26 |
2011-02-10 |
Canon Inc |
化合物
|
|
ES2534085T3
(es)
|
2009-08-17 |
2015-04-17 |
Roche Glycart Ag |
Inmunoconjugados dirigidos
|
|
EP2553101A4
(en)
|
2010-04-02 |
2013-09-04 |
Univ Rochester |
PROTEASE-ACTIVATED CYTOKINES
|
|
US9193791B2
(en)
|
2010-08-03 |
2015-11-24 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects
|
|
MX340556B
(es)
|
2010-08-24 |
2016-07-14 |
Roche Glycart Ag |
Anticuerpos biespecificos activables.
|
|
WO2012028697A1
(en)
|
2010-09-01 |
2012-03-08 |
Eth Zürich, Institute Of Molecular Biology And Biophysics |
Affinity purification system based on donor strand complementation
|
|
JP6130307B2
(ja)
|
2011-03-17 |
2017-05-17 |
ザ ユニバーシティ オブ バーミンガム |
再指向性免疫療法
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
CN104185474B
(zh)
|
2012-03-30 |
2017-08-25 |
拜尔健康护理有限责任公司 |
蛋白酶调节的抗体
|
|
WO2013180834A2
(en)
|
2012-04-06 |
2013-12-05 |
Omeros Corporation |
Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria
|
|
JP6178846B2
(ja)
|
2012-05-22 |
2017-08-09 |
ライフ テクノロジーズ エーエス |
組み換え抗体組成物およびその使用方法
|
|
MX2014016038A
(es)
|
2012-06-22 |
2015-08-14 |
Cytomx Therapeutics Inc |
Anticuerpos de reaccion cruzada anti - jagged 1 / jagged 2, anticuerpos anti - jagged activables y metodos para uso de los mismos.
|
|
US9487590B2
(en)
|
2012-09-25 |
2016-11-08 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
|
|
US9850316B2
(en)
|
2013-02-15 |
2017-12-26 |
National University Corporation Kyoto Institute Of Technology |
Method for refolding antibody, process for producing refolded antibody, refolded antibody, and uses thereof
|
|
CA2925106C
(en)
|
2013-09-25 |
2023-11-14 |
Cytomx Therapeutics, Inc. |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
|
WO2015066279A2
(en)
|
2013-10-30 |
2015-05-07 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
US9737623B2
(en)
|
2013-12-11 |
2017-08-22 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
IL270562B
(en)
|
2014-01-31 |
2022-08-01 |
Cytomx Therapeutics Inc |
Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
|
|
WO2015117930A1
(en)
|
2014-02-06 |
2015-08-13 |
F. Hoffmann-La Roche Ag |
Interleukine 10 immunoconjugates
|
|
JP7020909B2
(ja)
|
2014-07-25 |
2022-02-16 |
シトムクス セラピューティクス，インコーポレイティド |
抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
|
|
GB201413357D0
(en)
|
2014-07-28 |
2014-09-10 |
Philogen Spa |
Antibodies for treatment and diagnosis
|
|
AU2015323313B2
(en)
|
2014-09-25 |
2021-04-01 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
|
MX2017006016A
(es)
|
2014-11-11 |
2017-06-19 |
Amunix Operating Inc |
Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
|
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
|
CN108112254B
(zh)
|
2015-03-13 |
2022-01-28 |
西托姆克斯治疗公司 |
抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
|
|
EP3778640A1
(en)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
BR112017023862A2
(pt)
|
2015-05-04 |
2018-07-17 |
Cytomx Therapeutics Inc |
anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
|
|
CN107849133B
(zh)
|
2015-05-04 |
2022-08-23 |
西托姆克斯治疗公司 |
抗cd166抗体、可活化抗cd166抗体及其使用方法
|
|
CA2984892A1
(en)
|
2015-05-04 |
2016-11-10 |
Cytomx Therapeutics, Inc. |
Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
|
|
WO2016182064A1
(ja)
|
2015-05-13 |
2016-11-17 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
WO2017025698A1
(en)
|
2015-08-11 |
2017-02-16 |
Queen Mary University Of London |
Bispecific, cleavable antibodies
|
|
CR20180453A
(es)
|
2016-03-22 |
2018-12-05 |
Hoffmann La Roche |
Moleculas biespecíficas de células t activadas por proteasas
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
MX2019004775A
(es)
|
2016-11-03 |
2019-08-05 |
Squibb Bristol Myers Co |
Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos.
|
|
WO2018097308A1
(ja)
|
2016-11-28 |
2018-05-31 |
中外製薬株式会社 |
リガンド結合活性が調整可能なリガンド結合分子
|
|
TWI797097B
(zh)
|
2016-11-28 |
2023-04-01 |
日商中外製藥股份有限公司 |
包含抗原結合域與運送部分的多胜肽
|
|
US11180554B2
(en)
|
2016-12-13 |
2021-11-23 |
Astellas Pharma Inc. |
Anti-human CD73 antibody
|
|
EP3630818A1
(en)
|
2017-06-02 |
2020-04-08 |
Ablynx NV |
Aggrecan binding immunoglobulins
|
|
TW202428621A
(zh)
|
2017-06-02 |
2024-07-16 |
德商麥克專利有限公司 |
與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
|
|
US20210017247A1
(en)
|
2017-07-03 |
2021-01-21 |
Torque Therapeutics, Inc. |
Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
|
|
US20190038935A1
(en)
|
2017-08-07 |
2019-02-07 |
Timofey Ignatyev |
Exercise game and apparatus employing color-changing base locations
|
|
CN107602706B
(zh)
|
2017-10-16 |
2020-12-04 |
湖北大学 |
一种切割效率增强的hrv 3c蛋白酶底物突变体及其应用
|
|
CN111836828B
(zh)
|
2017-11-28 |
2024-12-20 |
中外制药株式会社 |
包括抗原结合结构域和运送部分的多肽
|
|
CN111630062A
(zh)
|
2017-11-28 |
2020-09-04 |
中外制药株式会社 |
具有可调节的配体结合活性的配体结合分子
|
|
KR102020131B1
(ko)
|
2017-12-29 |
2019-09-09 |
박성원 |
광경화성 조성물 및 이를 이용하여 제조된 성형품
|
|
WO2019173832A2
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
AU2019271148B9
(en)
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
CA3100005A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
US20210155701A1
(en)
|
2018-05-30 |
2021-05-27 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide comprising il-1r1 binding domain and carrying moiety
|
|
WO2019230868A1
(ja)
|
2018-05-30 |
2019-12-05 |
中外製薬株式会社 |
単ドメイン抗体含有リガンド結合分子
|
|
US12077577B2
(en)
|
2018-05-30 |
2024-09-03 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide comprising aggrecan binding domain and carrying moiety
|
|
US20210355219A1
(en)
|
2018-09-21 |
2021-11-18 |
Harpoon Therapeutics, Inc. |
Conditionally activated target-binding molecules
|
|
CN120463822A
(zh)
|
2018-09-27 |
2025-08-12 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
|
CN114127277A
(zh)
|
2019-06-05 |
2022-03-01 |
中外制药株式会社 |
蛋白酶底物和包含蛋白酶切割序列的多肽
|
|
JPWO2020246563A1
(https=)
|
2019-06-05 |
2020-12-10 |
|
|
|
MX2022000991A
(es)
|
2019-07-25 |
2022-05-24 |
Univ Chicago |
Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
|
|
CN115943210A
(zh)
|
2020-01-20 |
2023-04-07 |
中外制药株式会社 |
配体结合融合蛋白
|
|
JP2024527582A
(ja)
|
2021-07-19 |
2024-07-25 |
中外製薬株式会社 |
融合ポリペプチドを用いるプロテアーゼ媒介性の標的特異的サイトカイン送達
|